



Quarterly Healthcare Common Procedure Coding System (HCPCS) Drug/Biological Code Changes – July 2018 Update

MLN Matters Number: MM10624 **Revised**

Related Change Request (CR) Number: 10624

Related CR Release Date: July 5, 2018

Effective Date: July 1, 2018

Related CR Transmittal Number: R4083CP

Implementation Date: July 2, 2018

Note: This article was revised on July 6, 2018, to reflect a revised CR issued on July 5. The article is revised to show the Type of Service Code for CPT code 90739 remains as V. Also, the CR release date, transmittal number, and the Web address of the CR are revised. All other information is the same.

PROVIDER TYPES AFFECTED

This MLN Matters Article is intended for physicians, providers and suppliers billing Medicare Administrative Contractors (MACs) for services provided to Medicare beneficiaries.

PROVIDER ACTION NEEDED

Change Request (CR) 10624 informs MACs of updated drug/biological HCPCS codes. The HCPCS code set is updated on a quarterly basis. The July 2018 HCPCS file includes six new HCPCS codes: Q9991, Q9992, Q9993, Q9995, Q5105, and Q5106. Please make sure your billing staffs are aware of these updates.

BACKGROUND

The July 2018 HCPCS file includes six new HCPCS codes, which are payable by Medicare, effective for claims with dates of service on or after July 1, 2018. Part B payment for HCPCS code Q9995 will include the clotting factor furnishing fee. These codes are:

- **Q9991**
 - Short Description: Buprenorph xr 100 mg or less
 - Long Description: Injection, buprenorphine extended-release (sublocade), less than or equal to 100 mg
 - Type of Service (TOS) Code: 1
 - Medicare Physician Fee Schedule Data Base (MPFSDB) Status Indicator: E
- **Q9992**
 - Short Description: Buprenorphine xr over 100 mg

- Long Description: Injection, buprenorphine extended-release (sublocade), greater than 100 mg
- TOS Code: 1
- MPFSDB Status Indicator: E
- **Q9993**
 - Short Description: Inj., triamcinolone ext rel
 - Long Description: Injection, triamcinolone acetate, preservative-free, extended-release, microsphere formulation, 1 mg
 - TOS Code: 1,P
 - MPFSDB Status Indicator: E
- **Q9995**
 - Short Description: Inj. emicizumab-kxwh, 0.5 mg
 - Long Description: Injection, emicizumab-kxwh, 0.5 mg
 - TOS Code: 1
 - MPFSDB Status Indicator: E
- **Q5105**
 - Short Description: Inj Retacrit esrd on dialysi
 - Long Description: Injection, epoetin alfa, biosimilar, (Retacrit) (for esrd on dialysis), 100 units
 - TOS Code: 1, L
 - MPFSDB Status Indicator: E
- **Q5106**
 - Short Description: Inj Retacrit non-esrd use
 - Long Description: Injection, epoetin alfa, biosimilar, (Retacrit) (for non-esrd use), 1000 units
 - TOS Code: 9
 - MPFSDB Status Indicator: E

In addition to the new codes, the TOS code for CPT Code 90739 remains as V.

ADDITIONAL INFORMATION

The official instruction, CR 10624, issued to your MAC regarding this change is available at <https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/2018Downloads/R4083CP.pdf>.

If you have questions, your MACs may have more information. Find their website at <http://go.cms.gov/MAC-website-list>.

DOCUMENT HISTORY

Date of Change	Description
July 6, 2018	The article was revised to reflect a revised CR issued on July 5. The article is revised to show the Type of Service Code for CPT code 90739 remains as V. Also, the CR release date, transmittal number, and the Web address of the CR are revised. All other information is the same.
June 26, 2018	The article was revised to reflect a revised CR issued on June 26. In the article, the new codes of Q5105 and Q5106 are added. The Type of Service Code for CPT code 90739 is updated to 1, V. Also, the CR release date, transmittal number, and the Web address of the CR are revised. All other information is the same.
May 14, 2018	This article was revised to reflect a revised CR issued on May 11. In the article, a sentence is added to show that Part B payment for Q9995 includes the clotting factor furnishing fee. Also, the CR release date, transmittal number, and the Web address of the CR are revised. All other information is the same.
April 20, 2018	Initial article released.

Disclaimer: This article was prepared as a service to the public and is not intended to grant rights or impose obligations. This article may contain references or links to statutes, regulations, or other policy materials. The information provided is only intended to be a general summary. It is not intended to take the place of either the written law or regulations. We encourage readers to review the specific statutes, regulations and other interpretive materials for a full and accurate statement of their contents. CPT only copyright 2017 American Medical Association. All rights reserved.

Copyright © 2018, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the AHA copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB-04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312-893-6816. Making copies or utilizing the content of the UB-04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB-04 Manual and/or codes and descriptions; and/or making any commercial use of UB-04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. To license the electronic data file of UB-04 Data Specifications, contact Tim Carlson at (312) 893-6816 or Laryssa Marshall at (312) 893-6814. You may also contact us at ub04@healthforum.com

The American Hospital Association (the "AHA") has not reviewed, and is not responsible for, the completeness or accuracy of any information contained in this material, nor was the AHA or any of its affiliates, involved in the preparation of this material, or the analysis of information provided in the material. The views and/or positions presented in the material do not necessarily represent the views of the AHA. CMS and its products and services are not endorsed by the AHA or any of its affiliates.